Figure 4.
Radiosensitization of SK28 tumors by DT01 with a “palliative” RT protocol. Mice bearing subcutaneous SK28 melanoma tumor xenografts were untreated (NT), treated for 2 weeks with 10 fractions of 3 Gy (RT2w), treated for 2 weeks with six administrations of 4 mg of DT01 (DT012w), both treatments (RT2w + DT012w), or both treatments followed with a second cycle of DT01 6 weeks later (RT2w + DT012w + DT012w). (A) Treatment schedule. Each RT 3-Gy fraction is represented by a black triangle. Each DT01 4-mg administration is represented by a gray triangle. (B) Tumor growth. DT01 with RT significantly increased tumor growth control. (C) Survival. Mice were monitored until tumors reached 1500 mm3 (death time). Survival was significantly improved in mice treated with RT2w + DT012w and RT2w + DT012w + DT012w. Vt, tumor volume at a given time point; Vi, initial volume before treatment.